---
document_datetime: 2025-12-19 17:00:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/attrogy.html
document_name: attrogy.html
version: success
processing_time: 0.1066116
conversion_datetime: 2026-01-03 13:10:16.07264
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Attrogy

[RSS](/en/individual-human-medicine.xml/258588)

##### Authorised

This medicine is authorised for use in the European Union

diflunisal Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Attrogy](#news-on)
- [More information on Attrogy](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Attrogy is a medicine used to treat polyneuropathy (nerve damage) caused by hereditary transthyretin-mediated amyloidosis (hATTR), a disease in which abnormal proteins called amyloids build up in tissues around the body including around the nerves.

Attrogy is used in adults in the first two stages of the nerve damage (stage 1, when the patient has weakness in the legs but is able to walk unaided, and stage 2, when the patient can walk but needs help).

Attrogy contains the active substance diflunisal.

Expand section

Collapse section

## How is Attrogy used?

Attrogy can only be obtained with a prescription and is available as tablets to be taken by mouth. The recommended dose is one tablet twice a day with food.

For more information about using Attrogy, see the package leaflet or contact your doctor or pharmacist.

## How does Attrogy work?

In patients with hATTR amyloidosis, a protein called transthyretin which circulates in the blood is defective and breaks easily. The broken protein forms amyloid deposits in tissues and organs around the body, including around nerves, where it interferes with the normal organ function.

The active substance in Attrogy, diflunisal, belongs to the class of non-steroidal anti-inflammatory medicines and is also a stabiliser of transthyretin. Diflunisal attaches to transthyretin and prevents it from breaking up, thereby stopping the formation of amyloid deposits and slowing down the progression of the nerve disease.

## What benefits of Attrogy have been shown in studies?

In a main study involving 130 patients with hATTR and stage 1 or 2 nerve damage, Attrogy was shown to be more effective than placebo (a dummy treatment) at slowing the nerve damage progression caused by the disease.

The main measure of effectiveness was the change in the patients' symptoms of nerve damage, as measured by a standard scale called mNIS+7, where a higher score indicates greater nerve damage. After 24 months of treatment, the average mNIS+7 score was 8.2 in patients taking Attrogy compared with 26.2 points in those taking placebo.

## What are the risks associated with Attrogy?

For the full list of side effects and restrictions with Attrogy, see the package leaflet.

The most common side effects with Attrogy (which may affect up to 1 in 10 people) include indigestion and heart burn.

Attrogy must not be used in patients who have had an acute (sudden) asthmatic attacks, urticaria (itchy rash), rhinitis (stuffy and runny nose) or angioedema (rapid swelling under the skin) caused by acetylsalicylic acid (also known as aspirin) or other related medicines called non-steroidal anti-inflammatory medicines. It must also not be used in patients who have bleeding in the gut, severely reduced kidney or liver function or severe heart failure. It must also not be used in the third trimester of pregnancy and in breast-feeding mothers.

## Why is Attrogy authorised in the EU?

Despite some limitations in the data such as the high number of patients who left the study because they needed a liver transplant, Attrogy was more effective than placebo in delaying nerve damage in patients with hATTR. In terms of safety, most side effects were mild or moderate in severity. The European Medicines Agency therefore decided that Attrogy's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Attrogy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Attrogy have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Attrogy are continuously monitored. Suspected side effects reported with Attrogy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Attrogy

Attrogy received a marketing authorisation valid throughout the EU on 17 July 2025.

Attrogy : EPAR - Medicine overview

Reference Number: EMA/153788/2025

English (EN) (116.49 KB - PDF)

**First published:** 28/08/2025

[View](/en/documents/overview/attrogy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-107)

български (BG) (142.96 KB - PDF)

**First published:**

28/08/2025

[View](/bg/documents/overview/attrogy-epar-medicine-overview_bg.pdf)

español (ES) (116.86 KB - PDF)

**First published:**

28/08/2025

[View](/es/documents/overview/attrogy-epar-medicine-overview_es.pdf)

čeština (CS) (139 KB - PDF)

**First published:**

28/08/2025

[View](/cs/documents/overview/attrogy-epar-medicine-overview_cs.pdf)

dansk (DA) (117.2 KB - PDF)

**First published:**

28/08/2025

[View](/da/documents/overview/attrogy-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.24 KB - PDF)

**First published:**

28/08/2025

[View](/de/documents/overview/attrogy-epar-medicine-overview_de.pdf)

eesti keel (ET) (115.69 KB - PDF)

**First published:**

28/08/2025

[View](/et/documents/overview/attrogy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.94 KB - PDF)

**First published:**

28/08/2025

[View](/el/documents/overview/attrogy-epar-medicine-overview_el.pdf)

français (FR) (119.16 KB - PDF)

**First published:**

28/08/2025

[View](/fr/documents/overview/attrogy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.9 KB - PDF)

**First published:**

28/08/2025

[View](/hr/documents/overview/attrogy-epar-medicine-overview_hr.pdf)

italiano (IT) (116.03 KB - PDF)

**First published:**

28/08/2025

[View](/it/documents/overview/attrogy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (153.46 KB - PDF)

**First published:**

28/08/2025

[View](/lv/documents/overview/attrogy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138 KB - PDF)

**First published:**

28/08/2025

[View](/lt/documents/overview/attrogy-epar-medicine-overview_lt.pdf)

magyar (HU) (137 KB - PDF)

**First published:**

28/08/2025

[View](/hu/documents/overview/attrogy-epar-medicine-overview_hu.pdf)

Malti (MT) (140.29 KB - PDF)

**First published:**

28/08/2025

[View](/mt/documents/overview/attrogy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.54 KB - PDF)

**First published:**

28/08/2025

[View](/nl/documents/overview/attrogy-epar-medicine-overview_nl.pdf)

polski (PL) (142.69 KB - PDF)

**First published:**

28/08/2025

[View](/pl/documents/overview/attrogy-epar-medicine-overview_pl.pdf)

português (PT) (117.77 KB - PDF)

**First published:**

28/08/2025

[View](/pt/documents/overview/attrogy-epar-medicine-overview_pt.pdf)

română (RO) (136.34 KB - PDF)

**First published:**

28/08/2025

[View](/ro/documents/overview/attrogy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (138.95 KB - PDF)

**First published:**

28/08/2025

[View](/sk/documents/overview/attrogy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.18 KB - PDF)

**First published:**

28/08/2025

[View](/sl/documents/overview/attrogy-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.66 KB - PDF)

**First published:**

28/08/2025

[View](/fi/documents/overview/attrogy-epar-medicine-overview_fi.pdf)

svenska (SV) (115.71 KB - PDF)

**First published:**

28/08/2025

[View](/sv/documents/overview/attrogy-epar-medicine-overview_sv.pdf)

Attrogy : EPAR - Risk management plan

English (EN) (581.93 KB - PDF)

**First published:** 28/08/2025

**Last updated:** 17/09/2025

[View](/en/documents/rmp/attrogy-epar-risk-management-plan_en.pdf)

## Product information

Attrogy : EPAR - Product information

English (EN) (343.3 KB - PDF)

**First published:** 28/08/2025

**Last updated:** 19/12/2025

[View](/en/documents/product-information/attrogy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-862)

български (BG) (446.94 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/attrogy-epar-product-information_bg.pdf)

español (ES) (350.46 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/es/documents/product-information/attrogy-epar-product-information_es.pdf)

čeština (CS) (454.06 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/attrogy-epar-product-information_cs.pdf)

dansk (DA) (357.57 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/da/documents/product-information/attrogy-epar-product-information_da.pdf)

Deutsch (DE) (367.51 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/de/documents/product-information/attrogy-epar-product-information_de.pdf)

eesti keel (ET) (372.44 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/et/documents/product-information/attrogy-epar-product-information_et.pdf)

ελληνικά (EL) (431.8 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/el/documents/product-information/attrogy-epar-product-information_el.pdf)

français (FR) (358.29 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/attrogy-epar-product-information_fr.pdf)

hrvatski (HR) (414.14 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/attrogy-epar-product-information_hr.pdf)

íslenska (IS) (305.39 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/is/documents/product-information/attrogy-epar-product-information_is.pdf)

italiano (IT) (344.69 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/it/documents/product-information/attrogy-epar-product-information_it.pdf)

latviešu valoda (LV) (435.5 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/attrogy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (421.98 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/attrogy-epar-product-information_lt.pdf)

magyar (HU) (440.94 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/attrogy-epar-product-information_hu.pdf)

Malti (MT) (451.79 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/attrogy-epar-product-information_mt.pdf)

Nederlands (NL) (364.87 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/attrogy-epar-product-information_nl.pdf)

norsk (NO) (324.77 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/no/documents/product-information/attrogy-epar-product-information_no.pdf)

polski (PL) (460.76 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/attrogy-epar-product-information_pl.pdf)

português (PT) (378.39 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/attrogy-epar-product-information_pt.pdf)

română (RO) (450.07 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/attrogy-epar-product-information_ro.pdf)

slovenčina (SK) (461.74 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/attrogy-epar-product-information_sk.pdf)

slovenščina (SL) (442.13 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/attrogy-epar-product-information_sl.pdf)

Suomi (FI) (346.17 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/attrogy-epar-product-information_fi.pdf)

svenska (SV) (373.32 KB - PDF)

**First published:**

28/08/2025

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/attrogy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000301554 11/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Attrogy : EPAR - All authorised presentations

English (EN) (42.96 KB - PDF)

**First published:** 28/08/2025

[View](/en/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-155)

български (BG) (53.75 KB - PDF)

**First published:**

28/08/2025

[View](/bg/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.53 KB - PDF)

**First published:**

28/08/2025

[View](/es/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.09 KB - PDF)

**First published:**

28/08/2025

[View](/cs/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (45.63 KB - PDF)

**First published:**

28/08/2025

[View](/da/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (45.47 KB - PDF)

**First published:**

28/08/2025

[View](/de/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.65 KB - PDF)

**First published:**

28/08/2025

[View](/et/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.11 KB - PDF)

**First published:**

28/08/2025

[View](/el/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_el.pdf)

français (FR) (44.94 KB - PDF)

**First published:**

28/08/2025

[View](/fr/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (59.18 KB - PDF)

**First published:**

28/08/2025

[View](/hr/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (45.27 KB - PDF)

**First published:**

28/08/2025

[View](/is/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (44.73 KB - PDF)

**First published:**

28/08/2025

[View](/it/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (67.55 KB - PDF)

**First published:**

28/08/2025

[View](/lv/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.64 KB - PDF)

**First published:**

28/08/2025

[View](/lt/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (61.59 KB - PDF)

**First published:**

28/08/2025

[View](/hu/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (62.51 KB - PDF)

**First published:**

28/08/2025

[View](/mt/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.74 KB - PDF)

**First published:**

28/08/2025

[View](/nl/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.25 KB - PDF)

**First published:**

28/08/2025

[View](/no/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.53 KB - PDF)

**First published:**

28/08/2025

[View](/pl/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.23 KB - PDF)

**First published:**

28/08/2025

[View](/pt/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_pt.pdf)

română (RO) (52.28 KB - PDF)

**First published:**

28/08/2025

[View](/ro/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.63 KB - PDF)

**First published:**

28/08/2025

[View](/sk/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (62.11 KB - PDF)

**First published:**

28/08/2025

[View](/sl/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.67 KB - PDF)

**First published:**

28/08/2025

[View](/fi/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (44.69 KB - PDF)

**First published:**

28/08/2025

[View](/sv/documents/all-authorised-presentations/attrogy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Attrogy Active substance diflunisal International non-proprietary name (INN) or common name diflunisal Therapeutic area (MeSH) Amyloid Neuropathies, Familial Anatomical therapeutic chemical (ATC) code N02BA11

### Pharmacotherapeutic group

- Other analgesics and antipyretics
- Salicylic acid and derivatives

### Therapeutic indication

Attrogy is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.

## Authorisation details

EMA product number EMEA/H/C/006248

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Purpose Pharma International AB

Grev Turegatan 13b Engelbrekt 114 46 Stockholm Sweden

Opinion adopted 25/04/2025 Marketing authorisation issued 17/07/2025 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Attrogy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (121.74 KB - PDF)

**First published:** 19/12/2025

[View](/en/documents/procedural-steps-after/attrogy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Attrogy : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000247185

English (EN) (299.31 KB - PDF)

**First published:** 28/08/2025

[View](/en/documents/orphan-maintenance-report/attrogy-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Attrogy : EPAR - Public assessment report

Adopted

Reference Number: EMA/161582/2025

English (EN) (3.35 MB - PDF)

**First published:** 28/08/2025

[View](/en/documents/assessment-report/attrogy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Attrogy

Adopted

Reference Number: EMA/CHMP/134824/2025

English (EN) (92.88 KB - PDF)

**First published:** 25/04/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-attrogy_en.pdf)

#### News on Attrogy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2025) 25/04/2025

#### More information on Attrogy

- [EU/3/22/2640 - orphan designation for treatment of ATTR amyloidosis](/en/medicines/human/orphan-designations/eu-3-22-2640)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)